← Back to Clinical Trials
Recruiting NCT06264258

NCT06264258 Game-based Pediatric Diabetes Education

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06264258
Status Recruiting
Phase
Sponsor Carnegie Mellon University
Condition Diabetes Mellitus, Type 1
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-05-22
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 12 Years
Study Type INTERVENTIONAL
Interventions
DVx-T1D™ app

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-05-22 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to evaluate the impact of a mobile app video game called Digital Vaccine for Type 1 Diabetes (DVx-T1D)™, proposed as a low-risk, non-invasive, digital therapeutic candidate for behavior change in children 6 to 12 years of age with Type 1 Diabetes (T1D). The investigators hypothesize that adoption of DVx-T1D™ by T1D patients will positively influence healthy dietary and physical activity behaviors by providing nutrition and lifestyle education through a playful, Artificial Intelligence (AI)-based, cartoon-style medium of mobile gaming, and result in improvements in their T1D control. The investigators propose to conduct a longitudinal randomized controlled trial (RCT) over a 3-month period with a study population of 80 T1D participants (40 each in two arms of the trial) of 6-12 years old. The investigators will quantify the impact of the mobile game app plus standard care vs. standard care (with no exposure to the app) on T1D control (assessed by glycosylated hemoglobin or HbA1c measured during clinic visits and continuous glucose monitoring (CGM) parameters measured at home), physical activity levels and food choices of children (measured using food logs and surveys). Game telemetry, food logs, clinical, anthropometric, demographic, and survey data will be collected to obtain adequately powered, theory-driven evidence of the value of game-based approaches delivered via mobile apps.

Eligibility Criteria

For youth: * Be between the age of 6 to 12 years. * Have been diagnosed with type 1 diabetes for at least 1 year. * Be currently taking insulin through multiple daily injections or an insulin pump. * Check blood sugar with a meter at least 4 times per day or use a continuous glucose monitor. * Be willing to comply with all study visits and procedures. For Parent: * Biological or adopted parent with custody and medical decision making of the patients * Living with identified patients * Over 18 years old * Resident of Allegheny County Exclusion Criteria: -Children with type 2 diabetes, cystic fibrosis related diabetes, or secondary diabetes.

Contact & Investigator

Central Contact

Rema Padman, PhD

✉ rpadman@andrew.cmu.edu

📞 412-268-2180

Frequently Asked Questions

Who can join the NCT06264258 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 12 Years, studying Diabetes Mellitus, Type 1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06264258 currently recruiting?

Yes, NCT06264258 is actively recruiting participants. Contact the research team at rpadman@andrew.cmu.edu for enrollment information.

Where is the NCT06264258 trial being conducted?

This trial is being conducted at Pittsburgh, United States.

Who is sponsoring the NCT06264258 clinical trial?

NCT06264258 is sponsored by Carnegie Mellon University. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology